MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. (NASDAQ: MNKD) is a biopharmaceutical company focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T (iNKT) cells. The company's website is www.minktherapeutics.com.

The company's core approach centers on iNKT cells, a distinct immune cell population that uniquely bridges innate and adaptive immunity, combining the rapid cytolytic capabilities of natural killer cells with the durable memory responses of adaptive T cells. This dual functionality enables direct tumor killing, orchestration of the tumor microenvironment, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function while naturally suppressing graft-versus-host disease.

MiNK's lead product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy currently in Phase 2 clinical development across multiple indications. The company has treated nearly 100 patients with agenT-797 across oncology and critical pulmonary immune failure. In oncology, Phase 1 data demonstrated durable clinical activity in heavily pretreated, checkpoint-refractory cancers including metastatic testicular cancer, gastric cancer, thymoma, and cholangiocarcinoma. In pulmonary diseases, a Phase 1/2 study in mechanically ventilated patients with severe viral acute respiratory distress syndrome showed 30-day survival exceeding 70 percent, compared to approximately 10 percent in contemporaneous controls. The company is advancing a randomized Phase 2 trial in patients with severe pneumonia and moderate-to-severe hypoxemic acute respiratory failure.

Beyond native iNKT therapies, MiNK is developing engineered iNKT cell candidates, including MiNK-413, a BCMA-CAR-iNKT program, and MiNK-215, a FAP-CAR-iNKT program targeting solid tumors. The company operates a proprietary, closed-system cGMP manufacturing facility in Lexington, Massachusetts, designed to produce thousands of doses per healthy donor with over 99 percent iNKT cell purity. MiNK maintains strategic collaborations with Agenus Inc. for immuno-oncology combination therapies and partnerships with C-Further, Autonomous Therapeutics, and Immunoscape to advance TCR-based and other complementary technologies.